1 / 20

Features of Canine Conjunctival Melanocytic Tumors

Features of Canine Conjunctival Melanocytic Tumors. Reilly CM, Dubielzig RR, Newman SJ and Bergman PJ. Purposes. A retrospective study of the histologic and biologic features of canine conjunctival melanocytic tumors Compare to results of prior studies

tgail
Download Presentation

Features of Canine Conjunctival Melanocytic Tumors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Features of Canine Conjunctival Melanocytic Tumors Reilly CM, Dubielzig RR, Newman SJ and Bergman PJ

  2. Purposes • A retrospective study of the histologic and biologic features of canine conjunctival melanocytic tumors • Compare to results of prior studies • Biologic behavior and histologic characteristics of canine conjunctival melanomas. Collins BK, Collier LL, Miller MA, Linton LL. Prog in vet and comparative ophthalmology; 3:135-140, 1993.

  3. Methods • Cases of conjunctival melanocytic tumors selected (COPLOW and AMC) • Follow-up surveys mailed to submitting ophthalmologists • Only cases with follow-up available were included

  4. Methods (cont.) • Slides were evaluated for: • Pigmentation • Intra- and subepithelial packeting • Criteria of malignancy • Cell type(s) • Mitotic index • Necrosis • Epithelial dysplasia

  5. Methods (cont.) • Survey information included: • Breed, gender, age at diagnosis • Tumor location (bulbar, TEL, palpebral) • Surgery type (incisional, excisional, enucleation, exenteration) • Recurrence, metastasis and death

  6. Results • 63 cases were identified • 24 had follow-up available • 14 males, 10 females • 8 mixed breeds, 3 labs, 2 cockers, 2 Weimaraners, 2 Shar-peis • 1 each Schnauzer, German Shepherd, Poodle, Golden Retriever, Boston Terrier, Pekingese, Newfoundland • Age at diagnosis 6-14 y (11.5)

  7. Results – Location • 14/23 (61%) on TEL • 5/23 (22%) on bulbar conjunctiva • 4/23 (17%) on palpebral conjunctiva • Location not provided for one tumor

  8. Results - Histologic patterns • 14/24 (60%) had packeting of neoplastic cells within conj. epithelium • 19/24 (83%) had packeting in subepithelial stroma • No correlation with recurrence or metastasis • Can be helpful in diagnosis of amelanotic tumors

  9. Results – Benign tumors • 3/24 (12%) histologically benign (melanocytomas) • None had necrosis, mitoses or dysplasia • None recurred or metastasized • One was multicentric at diagnosis

  10. Results - malignant • 17/21 (81%) at least partially pigmented • 5/21 (24%) were spindle cell type • 7/21 (33%) were “epithelioid” type • 9/21 (43%) were a mixture of both

  11. Results - Recurrence • 10/21 (48%) tumors recurred • 4/12 (33%) TEL tumors • 2/10 (20%) w/ marginal excision • 2/3 (67%) w/ complete TEL excision • 2/4 (50%) bulbar tumors • 3/4 (75%) palpebral tumors • One tumor (TEL) had multicentric recurrence

  12. Results – Tumor related death • Only 2 tumors (10%) metastasized • Both from palpebral conjunctiva • 1 dog (5%) euthanized for aggressive regrowth • Also from palpebral conjunctiva • No dogs with TEL or bulbar tumors died from tumor • Palpebral tumors more advanced at diagnosis?

  13. Conclusions • Similar to prior report EXCEPT: • Even male: female ratio • Shar-peis also over represented • Metastatic risk may be lower (10% v. 17%) • Recurrence even with aggressive surgery • Stresses the need for assertive follow-up • Especially rare diseases

  14. Acknowledgements • Co-authors: Dr. Dick Dubielzig, Rebecca Morris, Dr. Shelley Newman, Dr. Phillip Bergman • Technical Assistance: Kate Leiber

  15. Questions?

More Related